<DOC>
	<DOCNO>NCT02804568</DOCNO>
	<brief_summary>This study determine safety , tolerability , pharmacokinetics ( PK ) olanzapine samidorphan adult schizophrenia follow 14 consecutive day oral administration ALKS 3831 .</brief_summary>
	<brief_title>A Phase 1 Safety Study Adults With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Has body mass index ( BMI ) 18.035.0 kg/m^2 , inclusive Has primary diagnosis schizophrenia Capable understand complying procedure , requirement , restriction protocol . Appropriate outpatient treatment Agrees abide contraception requirement specify protocol duration study surgically sterile Willing able provide governmentissued identification Is good physical health Agrees maintain normal tobacco use well normal activities/exercise throughout study Additional criterion may apply Is currently pregnant breastfeed Initiated first antipsychotic treatment within past 12 month , &lt; 1 year elapse since initial onset activephase schizophrenia symptoms Poses current suicide risk Visits 1 2 Has history poor inadequate response treatment olanzapine Has use longacting injectable antipsychotic medication last 6 month exception 3month paliperidone , must receive within past 12 month . Requires electroconvulsive therapy ( ECT ) treatment 6month period prior Visit 1 Has diagnosis alcohol drug use disorder ( exception nicotine ) Has take opioid agonist ( codeine , oxycodone , tramadol , morphine ) within 14 day prior Visit 1 and/or anticipates need take opioid medication study period . Has take opioid antagonist include naltrexone ( formulation ) naloxone within 60 day prior Visit 1 , use extendedrelease formulation opioid antagonist within 2 month prior screen Tests positive amphetamines/methamphetamine , cocaine , barbiturate , opioids ( codeine , hydrocodone , hydromorphone , methadone , morphine , oxycodone , oxymorphone , buprenorphine ) , phencyclidine benzodiazepine . Has know suspect intolerance , allergy hypersensitivity olanzapine opioid antagonist . Additional criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Alkermes</keyword>
	<keyword>ALK 3831</keyword>
	<keyword>Samidorphan</keyword>
</DOC>